<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414529</url>
  </required_header>
  <id_info>
    <org_study_id>12-03213</org_study_id>
    <nct_id>NCT02414529</nct_id>
  </id_info>
  <brief_title>Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents</brief_title>
  <official_title>Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether giving a Vitamin D supplement to vitamin D&#xD;
      deficient obese children and adolescents will decrease the risk of getting diabetes (Disease&#xD;
      in which the person has high blood sugar).&#xD;
&#xD;
      The number of vitamin D deficiency in U.S. children and teenagers has grown dramatically over&#xD;
      the past 30 years. There are some reports suggesting that vitamin D supplementation in adults&#xD;
      with pre diabetes (blood glucose higher than normal) and vitamin D treatment will prevent&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation will involve 3 visits (6 weeks apart) to the Clinical and Translational Science&#xD;
      Institute (CTSI), which should happen 2-3 weeks after you have consented to participate in&#xD;
      this study. The total duration of the study and the time you/your child will spend in the&#xD;
      CTSI will be 2.5 hours for each visit.&#xD;
&#xD;
      Number of adolescents/children will enroll in this study:20.&#xD;
&#xD;
      Visit 1 A doctor will perform a complete physical examination. The child will have his/her&#xD;
      weight and height measured .Blood pressure and vital signs will check each visit.&#xD;
&#xD;
      Of the 2 hours spent in the hospital, 1/2 hour is allocated to getting measurements, weight,&#xD;
      and vitals and putting in an intravenous line and drawing fasting labs. The oral glucose&#xD;
      tolerance test will take about 2 hours. To test for insulin sensitivity (Risk marker of&#xD;
      Diabetes), oral Glucose Tolerance Test (OGTT) will be done. OGTT is used to diagnose Diabetes&#xD;
      and Pre Diabetes. The child will first have blood samples drawn, and then will drink oral&#xD;
      glucose soda. Blood samples will be obtained over 2 hours. A total of 5-7 teaspoons, which is&#xD;
      25-35 cc of blood will be taken during this test. Of this 15 cc will be drawn during the&#xD;
      OGTT. A doctor or nurse will be monitoring the child throughout the test. If he/she develops&#xD;
      low blood sugar, they will be treated appropriately with glucose.&#xD;
&#xD;
      Blood samples obtained at the start of the OGTT will be used to measure various markers of&#xD;
      insulin sensitivity, vitamin D level and marker of bone health as vitamin D deficiency can&#xD;
      causebone loss. This blood will be stored in the CTSI core laboratory in the CTSI for&#xD;
      duration of this study. The blood samples will be stored without child's name or any other&#xD;
      identifying information on them. The samples will be destroyed once the study is completed.&#xD;
&#xD;
      After the OGTT done, your child will receive a one time high dose of vitamin D (group A) or&#xD;
      placebo (capsule containing no medication) (Group B). This way of treating of low vitamin D&#xD;
      levels with one time high dose of vitamin D is safe and has been studied in adolescents.&#xD;
&#xD;
      The child has 50/50 chance to be in either group. Neither he/she nor you will know if he/she&#xD;
      is getting Vit D or placebo. At week 7, your child needs to return to CTSI for 2nd study for&#xD;
      physical check-up, blood test and urine test using the same method as the 1st visit. The&#xD;
      urine testing will be done to test for urinary calcium as this could be a sign of vitamin D&#xD;
      toxicity.&#xD;
&#xD;
      After the 2nd study done, your child will be reassigned to alternate treatment group and will&#xD;
      receive either vitamin D or placebo. That means that if he/she was getting a placebo at the&#xD;
      first visit then he/she will get a real Vit D this time. If he/she was getting vit D at the&#xD;
      first visit, he/she will get a placebo at this visit.&#xD;
&#xD;
      At week 12 after completion of the 2nd course of medication, you and your child will have to&#xD;
      come back for the final blood and urine study using the same method as the first and 2nd&#xD;
      study.&#xD;
&#xD;
      At this your child will have an oral glucose tolerance test, blood and urine tests. The urine&#xD;
      testing will be done to test for urinary calcium as this could be a sign of vitamin D&#xD;
      toxicity. If your child has high urine calcium he/she will not be allowed to participate in&#xD;
      the study We guarantee that your child will receive the treatment for lack of vitamin D&#xD;
      either the first half or latter half of the study. However, you will not know what medication&#xD;
      your child will receive during the entire study. We will set an appointment to see us in&#xD;
      2weeks at the Endocrine clinic; however, it will be not part of the study. We will go over&#xD;
      the results of the study at that time and will see if any further treatment with Vitamin D is&#xD;
      required for your adolescent.&#xD;
&#xD;
      You and your child will have to come back to CTSI at the end of week 12 for post-therapy&#xD;
      study. After a minimum 10-hour fast, participants will come to the CTSI, during which your&#xD;
      child will have his/her weight and height measured. Blood Pressure will be measured. Post&#xD;
      vitamin D therapy OGTT. Vitamin D level and markers for bone health will again be measured&#xD;
      using same method as day 1. Urine will be collected for urinary calcium level, using same&#xD;
      method as day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Body Insulin Sensitivity (WBISI)</measure>
    <time_frame>18 weeks</time_frame>
    <description>measured by the OGTT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulinogenic index</measure>
    <time_frame>18 weeks</time_frame>
    <description>meassured by OGT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D 25 OH</measure>
    <time_frame>18 weeks</time_frame>
    <description>pre and post treatment changes in serum vitamin D 25 OH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTH level</measure>
    <time_frame>18 weeks</time_frame>
    <description>changes in the level PTH pre and post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D toxicity</measure>
    <time_frame>18 weeks</time_frame>
    <description>will measure metabolic profile to monitor toxicity such us: calcium level in serum and urine, phosphate, vitamin D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.&#xD;
Subjects are blinded then they will crossover groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.&#xD;
Subjects are blinded then they will crossover groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D2</intervention_name>
    <description>Ergocalciferol 5000 units capsules given. 300,000 units PO once.</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>ergocalciferol, Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Obese subjects - BMI at or above the 95th percentile for children of the same age and&#xD;
             sex. Only obese subjects will be selected given that they are the highest risk group&#xD;
             of developing insulin resistance and Type II Diabetes and therefore with be most&#xD;
             likely to demonstrate glucose pertubation.&#xD;
&#xD;
          2. Pubertal: Testicular volume â‰¥ 6 ml Prader (M) and Tanner III breast development or&#xD;
             greater (F)&#xD;
&#xD;
          3. 12- 18 years regardless of gender, race or economic circumstance&#xD;
&#xD;
          4. Pre diabetes/high risk of diabetes using criteria of HbA1C between 5.7 - 6.4% as&#xD;
             defined by the American Diabetes Association (ADA)&#xD;
&#xD;
          5. 25-OH vitamin D level less than 20 ng/ml (50 nmol/liter)&#xD;
&#xD;
          6. Subjects must be willing to comply with study protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment on medication known to effect vitamin D, calcium and glucose metabolism,&#xD;
             such as glucocorticoids, thiazolidinediones, metformin, anticonvulsants metabolized&#xD;
             through cytochrome P-450 (phenytoin, carbamazepine, phenobarbital, sodium valproate).&#xD;
&#xD;
          2. Subjects will be excluded from the study if they have taken any form of vitamin D&#xD;
             supplementation greater than 400 IU daily in the preceding 3 months.&#xD;
&#xD;
          3. Significant major organ system illness&#xD;
&#xD;
          4. History of nephrolithiasis or hypercalcemia&#xD;
&#xD;
          5. Females who are pregnant&#xD;
&#xD;
          6. Significant psychiatric illness: schizophrenia, bipolar disorder, active substance&#xD;
             abuse, and uncontrolled major depression.&#xD;
&#xD;
          7. Attendance at tanning salon&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Preneet Brar</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>bellevue hospital CTSI</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

